ArriVent BioPharma, Inc. 8-K

What Happened
ArriVent BioPharma, Inc. (AVBP) announced on March 17, 2026 (via an 8-K and press release) that it will present two preclinical posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The posters describe preclinical data for firmonertinib (an EGFR inhibitor) and ARR-002 (a novel dual‑target MUC16/NaPi2b tetravalent antibody‑drug conjugate).

Key Details

• Announcement filed in Form 8-K on March 17, 2026; press release included as Exhibit 99.1.
• Two preclinical poster presentations planned for the 2026 AACR Annual Meeting.
• Programs highlighted: firmonertinib (EGFR inhibitor) and ARR-002 (MUC16/NaPi2b tetravalent ADC).
• Disclosure made under Regulation FD (public release of company information).

Why It Matters
This filing signals public disclosure of preclinical progress for two pipeline candidates, which is relevant for investors tracking ArriVent’s drug-development milestones. While the filing does not report clinical results or financial data, upcoming AACR presentations could provide more scientific detail on the programs and help the market assess development prospects. The 8-K ensures the information was shared publicly and not selectively.